The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study.
 
Qu Liu
No Relationships to Disclose
 
Zhengyu Chang
No Relationships to Disclose
 
Guodong Zhao
No Relationships to Disclose
 
Yuanxing Gao
No Relationships to Disclose
 
Xianglong Tan
No Relationships to Disclose
 
Xuan Zhang
No Relationships to Disclose
 
Hailong Jin
No Relationships to Disclose
 
Rong Liu
No Relationships to Disclose